ArticleScientific reports2025
Integrated multi-omics analysis identifies lipid metabolism biomarkers in ONFH and reveals therapeutic potential of retinoic acid.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Osteonecrosis of the femoral head (ONFH) is a debilitating condition frequently associated with dysregulation in lipid metabolism. The objective of this study was to identify potential biomarkers for ONFH through various analytical methods and experimental verification, thereby providing a robust reference for disease treatment. Utilizing public datasets, differential analysis was conducted and integrated with weighted gene co-expression network analysis to pinpoint key genes. Subsequently, biomarkers related to lipid metabolism in ONFH were identified by combining machine learning techniques with receiver operating characteristic curves. Furthermore, based on these biomarkers, a nomogram model was developed for diagnostic prediction. Immune infiltration was assessed, and drug predictions involved molecular docking studies. Finally, the relationship between biomarkers and immune cells was investigated through single-cell analysis. Then the system experiment is carried out to verify. Thirty key genes were identified, primarily enriched in "phospholipid metabolic processes" and "lysosome". A total of three biomarkers-CREBBP, GLB1, and PSAP-were recognized as exhibiting strong diagnostic efficacy. The nomogram incorporating these biomarkers demonstrated accurate predictive capabilities. Immune infiltration analysis revealed altered levels of neutrophils and activated dendritic cells in ONFH that correlated with biomarker expression. Additionally, molecular docking studies indicated stable interactions between the identified biomarkers and potential therapeutic agents such as estradiol and retinoic acid. Single-cell sequencing analysis uncovered significant differences in biomarker expression across various immune cell types including T cells. Finally, it was verified that retinoic acid improved ONFH by hsa-miR-320a/GLB1 in vitro and in vivo. This study identifies CREBBP, GLB1, and PSAP as promising biomarkers for ONFH while underscoring their potential roles in lipid metabolism and immune modulation. Moreover, we confirmed the important conclusion that retinoic acid improves ONFH through hsa-miR-320a/GLB1. Future investigations into the therapeutic implications of these findings may offer new avenues for ONFH management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.